KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Clinical trial NCT06411691 · RECRUITING
Trial details
- NCT number
- NCT06411691
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-04
- Primary completion
- 2029-11-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.